The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double‐blind, placebo‐controlled phase 2 study

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-1241|69|2|242-250

ISSN： 1368-5031

Source： INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol.69, Iss.2, 2015-02, pp. : 242-250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and Safety of the Selective β3‐Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Finding Study

By  

LUTS, Vol. 7, Iss. 2, 2015-05 ,pp. : 84-92

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain

By Daniels Stephen   Casson Ed   Stegmann Jens-Ulrich   Oh Charles   Okamoto Akiko   Rauschkolb Christine   Upmalis David  

Current Medical Research and Opinion, Vol. 25, Iss. 6, 2009-06 ,pp. : 1551-1561

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

By Barzilai Nir   Guo Hua   Mahoney Erin M.   Caporossi Suzanne   Golm Gregory T.   Langdon Ronald B.   Williams-Herman Debora   Kaufman Keith D.   Amatruda John M.   Goldstein Barry J.   Steinberg Helmut  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 1049-1058

Informa Healthcare

Access to resources Recommend Favorite

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

By  

NEUROUROLOGY AND URODYNAMICS, Vol. 34, Iss. 7, 2015-09 ,pp. : 685-692

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects

By Watabe Mitsuo   Cheng Yi-Fang   Nilsson Dag   Itoh Yohji   Kumagai Yuji  

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1849-1857

Informa Healthcare

Access to resources Recommend Favorite